Recent News & Research

Oncology News Central
Advocacy

Empowered Choices: “The Most Important Conversations” Oncologists Can Have With NSCLC Patients

*July 2025* When it comes to treatment decisions for patients with EGFR-mutated non-small cell lung cancer, “the most important conversations are not the data-driven ones, they are the relational ones,” says patient advocate Jill Feldman. In the second episode of the LungCancerRx video podcast, cohosts Fawzi F. Abu Rous, MD, a thoracic medical oncologist…
laurabbook@gmail.com
November 20, 2025
Andrew Kasten
Coping With CancerStories

MEMBER SPOTLIGHT: Andrew Kasten

*July 2025* April Fools Day! It’s Lung Cancer! Andrew Kasten’s introduction to lung cancer started late in the afternoon on April 1, 2022. “I’m talking on the phone, and my left arm feels like it’s going numb,” said Andrew. The next day, on the way home from coaching his son’s…
laurabbook@gmail.com
November 20, 2025
Science Direct
ResearchTreatments

Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

*June 2025* Abstract Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC,…
laurabbook@gmail.com
November 19, 2025
Lung Cancer Journal
ResearchTreatments

Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors

*July 2025* Highlights --Mutations were more easily detected in CSF than in plasma of NSCLC leptomeningeal metastasis. --Genes enriched in CSF are altered in multiple oncogenic signaling pathways. --CSF exhibits significantly greater copy number variations and missense mutations than plasma. --Furmonertinib combined with bevacizumab, and high-dose pemetrexed for IVC can…
laurabbook@gmail.com
November 19, 2025
ResearchTreatments

Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States

*September 2025* Abstract Introduction Patients with NSCLC harboring EGFR mutations (EGFRm) have high mortality. The third-generation tyrosine kinase inhibitor, osimertinib, is approved for first-line EGFRm NSCLC. We used longitudinal U.S. medical oncology databases to evaluate real-world overall survival (rwOS) and prognostic risk factor groups in advanced EGFRm NSCLC treated with…
laurabbook@gmail.com
November 19, 2025